ANK-301
/ Ankyra Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 02, 2026
Alum-anchored CD40–IL-2 multi-agonist (ANK-301) promotes local and abscopal anti-tumor immunity without systemic toxicity
(SITC 2026)
- No abstract available
Oncology • CD40 • IL2
1 to 1
Of
1
Go to page
1